Acne Vulgaris – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Acne Vulgaris – Pipeline Review, H2 2019’, provides an overview of the Acne Vulgaris pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acne Vulgaris, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acne Vulgaris and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Acne Vulgaris

– The report reviews pipeline therapeutics for Acne Vulgaris by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Acne Vulgaris therapeutics and enlists all their major and minor projects

– The report assesses Acne Vulgaris therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Acne Vulgaris

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Acne Vulgaris

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Acne Vulgaris pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

Allianz Pharmascience Ltd

Amgen Inc

AOBiome LLC

Bausch Health Companies Inc

Biomimetix JV LLC

BioPharmX Inc

Boston Pharmaceuticals Inc

Botanix Pharmaceuticals Ltd

Boulos and Cooper Pharmaceuticals Pty Ltd

Cassiopea SpA

Cellix Bio Pvt Ltd

Cutanea Life Sciences Inc

Daewoong Co Ltd

Dermata Therapeutics LLC

Dermavant Sciences Inc

Devonian Health Group Inc

Eligo Bioscience SA

ELORAC Inc

Foamix Pharmaceuticals Ltd

Galderma SA

Helix BioMedix Inc

Innovation Pharmaceuticals Inc

Kalytera Therapeutics Inc

Lee’s Pharmaceutical Holdings Ltd

Melinta Therapeutics Inc

Mimetica Pty Ltd

Naked Biome Inc

Nogra Pharma Ltd

Novabiotics Ltd

Novan Inc

Novartis AG

Origimm Biotechnology GmbH

Ortho Dermatologics Inc

Phagelux Inc

PHI Therapeutics Inc

Phosphagenics Ltd

Photocure ASA

Promius Pharma LLC

Provectus Biopharmaceuticals Inc

Riptide Bioscience Inc

Sanotize Research And Development Corp

Sebela Pharmaceuticals Inc

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Sol-Gel Technologies Ltd

Sun Pharma Advanced Research Company Ltd

Union Therapeutics AS

Vyome Therapeutics Inc

XBiotech Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Acne Vulgaris - Overview 6

Acne Vulgaris - Therapeutics Development 7

Acne Vulgaris - Therapeutics Assessment 16

Acne Vulgaris - Companies Involved in Therapeutics Development 24

Acne Vulgaris - Drug Profiles 38

Acne Vulgaris - Dormant Projects 161

Acne Vulgaris - Discontinued Products 167

Acne Vulgaris - Product Development Milestones 168

Appendix 179

List of Tables

List of Tables

Number of Products under Development for Acne Vulgaris, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Acne Vulgaris – Pipeline by 3SBio Inc, H2 2019

Acne Vulgaris – Pipeline by Allianz Pharmascience Ltd, H2 2019

Acne Vulgaris – Pipeline by Amgen Inc, H2 2019

Acne Vulgaris – Pipeline by AOBiome LLC, H2 2019

Acne Vulgaris – Pipeline by Bausch Health Companies Inc, H2 2019

Acne Vulgaris – Pipeline by Biomimetix JV LLC, H2 2019

Acne Vulgaris – Pipeline by BioPharmX Inc, H2 2019

Acne Vulgaris – Dormant Projects, H2 2019

Acne Vulgaris – Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development for Acne Vulgaris, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports